<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36405695</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis.</ArticleTitle><Pagination><StartPage>1035151</StartPage><MedlinePgn>1035151</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1035151</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1035151</ELocationID><Abstract><AbstractText Label="BACKGROUND">Since the global epidemic of the coronavirus disease 2019 (COVID-19), a large number of immunological studies related to COVID-19 have been published in various immunology journals. However, the results from these studies were discrete, and no study summarized the important immunological information about COVID-19 released by these immunology journals. This study aimed to comprehensively summarize the knowledge structure and research hotspots of COVID-19 published in major immunology journals through bibliometrics.</AbstractText><AbstractText Label="METHODS">Publications on COVID-19 in major immunology journals were obtained from the Web of Science Core Collection. CiteSpace, VOSviewer, and R-bibliometrix were comprehensively used for bibliometric and visual analysis.</AbstractText><AbstractText Label="RESULTS">1,331 and 5,000 publications of 10 journals with high impact factors and 10 journals with the most papers were included, respectively. The USA, China, England, and Italy made the most significant contributions to these papers. University College London, National Institute of Allergy and Infectious Diseases, Harvard Medical School, University California San Diego, and University of Pennsylvania played a central role in international cooperation in the immunology research field of COVID-19. Yuen Kwok Yung was the most important author in terms of the number of publications and citations, and the H-index. <i>CLINICAL INFECTIOUS DISEASES</i> and <i>FRONTIERS IN IMMUNOLOGY</i> were the most essential immunology journals. These immunology journals mostly focused on the following topics: "Delta/Omicron variants", "cytokine storm", "neutralization/neutralizing antibody", "T cell", "BNT162b2", "mRNA vaccine", "vaccine effectiveness/safety", and "long COVID".</AbstractText><AbstractText Label="CONCLUSION">This study systematically uncovered a holistic picture of the current research on COVID-19 published in major immunology journals from the perspective of bibliometrics, which will provide a reference for future research in this field.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Zhao, Zhu, Huang, Zhu, Zhu, Wu and Yuan.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jiefeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jinfeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiaojian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Digestive Disease, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Zhengming</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Qinrong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Yingtan City People's Hospital, Yingtan, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Rongfa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010506" MajorTopicYN="Y">Periodicals as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015706" MajorTopicYN="N">Bibliometrics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-ibliometric analysis</Keyword><Keyword MajorTopicYN="N">CiteSpace</Keyword><Keyword MajorTopicYN="N">R-bibliometrix</Keyword><Keyword MajorTopicYN="N">immunology journal</Keyword><Keyword MajorTopicYN="N">the coronavirus disease 2019 (COVID-19)</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>21</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36405695</ArticleId><ArticleId IdType="pmc">PMC9670819</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1035151</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tu B, Gao Y, An X, Wang H, Huang Y. Localized delivery of nanomedicine and antibodies for combating covid-19. Acta Pharm Sin B (2022). doi:&#xa0;10.1016/j.apsb.2022.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2022.09.011</ArticleId><ArticleId IdType="pmc">PMC9502448</ArticleId><ArticleId IdType="pubmed">36168329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankerhold J, Giese S, Kolb P, Maul-Pavicic A, Voll RE, G&#xf6;ppert N, et al. . Circulating multimeric immune complexes contribute to immunopathology in covid-19. Nat Commun (2022) 13(1):5654. doi:&#xa0;10.1038/s41467-022-32867-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32867-z</ArticleId><ArticleId IdType="pmc">PMC9513013</ArticleId><ArticleId IdType="pubmed">36163132</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb P, Giese S, Voll RE, Hengel H, Falcone V. Immune complexes as culprits of immunopathology in severe covid-19. Med Microbiol Immunol (2022), 1&#x2013;7. doi:&#xa0;10.1007/s00430-022-00743-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-022-00743-8</ArticleId><ArticleId IdType="pmc">PMC9308473</ArticleId><ArticleId IdType="pubmed">35871171</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuya K, Hattori T, Saito T, Takadate Y, Sasaki M, Furuyama W, et al. . Multiple routes of antibody-dependent enhancement of sars-Cov-2 infection. Microbiol Spectr (2022) 10(2):e0155321. doi:&#xa0;10.1128/spectrum.01553-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.01553-21</ArticleId><ArticleId IdType="pmc">PMC9045191</ArticleId><ArticleId IdType="pubmed">35319248</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim EHT, van Amstel RBE, de Boer VV, van Vught LA, de Bruin S, Brouwer MC, et al. . Complement activation in covid-19 and targeted therapeutic options: A scoping review. Blood Rev (2022) 100995. doi:&#xa0;10.1016/j.blre.2022.100995</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2022.100995</ArticleId><ArticleId IdType="pmc">PMC9338830</ArticleId><ArticleId IdType="pubmed">35934552</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in covid-19. Nat Rev Immunol (2022) 22(2):77&#x2013;84. doi:&#xa0;10.1038/s41577-021-00665-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00665-1</ArticleId><ArticleId IdType="pmc">PMC8672651</ArticleId><ArticleId IdType="pubmed">34912108</ArticleId></ArticleIdList></Reference><Reference><Citation>Boussier J, Yatim N, Marchal A, Hadjadj J, Charbit B, El Sissy C, et al. . Severe covid-19 is associated with hyperactivation of the alternative complement pathway. J Allergy Clin Immunol (2022) 149(2):550&#x2013;6.e2. doi:&#xa0;10.1016/j.jaci.2021.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.11.004</ArticleId><ArticleId IdType="pmc">PMC8595971</ArticleId><ArticleId IdType="pubmed">34800432</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, et al. . The first case of covid-19 treated with the complement C3 inhibitor Amy-101. Clin Immunol (2020) 215:108450. doi:&#xa0;10.1016/j.clim.2020.108450</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108450</ArticleId><ArticleId IdType="pmc">PMC7189192</ArticleId><ArticleId IdType="pubmed">32360516</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvelli J, Demaria O, Vely F, Batista L, Chouaki Benmansour N, Fares J, et al. . Association of covid-19 inflammation with activation of the C5a-C5ar1 axis. Nature (2020) 588(7836):146&#x2013;50. doi:&#xa0;10.1038/s41586-020-2600-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2600-6</ArticleId><ArticleId IdType="pmc">PMC7116884</ArticleId><ArticleId IdType="pubmed">32726800</ArticleId></ArticleIdList></Reference><Reference><Citation>McEneny-King AC, Monteleone JPR, Kazani SD, Ortiz SR. Pharmacokinetic and pharmacodynamic evaluation of ravulizumab in adults with severe coronavirus disease 2019. Infect Dis Ther (2021) 10(2):1045&#x2013;54. doi:&#xa0;10.1007/s40121-021-00425-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00425-7</ArticleId><ArticleId IdType="pmc">PMC8024938</ArticleId><ArticleId IdType="pubmed">33826106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, et al. . Eculizumab in patients with severe coronavirus disease 2019 (Covid-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PloS One (2021) 16(12):e0261113. doi:&#xa0;10.1371/journal.pone.0261113</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261113</ArticleId><ArticleId IdType="pmc">PMC8687582</ArticleId><ArticleId IdType="pubmed">34928990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Proschan M. Complement C5a inhibition: A new form of covid-19 treatment for mechanically ventilated patients? Lancet Respir Med (2022). doi:&#xa0;10.1016/s2213-2600(22)00365-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(22)00365-4</ArticleId><ArticleId IdType="pmc">PMC9467518</ArticleId><ArticleId IdType="pubmed">36108660</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Jalal NA, Kabrah SM, Alexiou A, Batiha GE. Sars-Cov-2 infection and C1-esterase inhibitor: Camouflage pattern and new perspective. Curr Protein Pept Sci (2022). doi:&#xa0;10.2174/1389203723666220811121803</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389203723666220811121803</ArticleId><ArticleId IdType="pubmed">35959625</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leeuw E, Van Damme KFA, Declercq J, Bosteels C, Maes B, Tavernier SJ, et al. . Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with covid-19: An open-label randomized controlled trial. Respir Res (2022) 23(1):202. doi:&#xa0;10.1186/s12931-022-02126-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02126-2</ArticleId><ArticleId IdType="pmc">PMC9361275</ArticleId><ArticleId IdType="pubmed">35945604</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastellos DC, Pires da Silva BGP, Fonseca BAL, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, et al. . Complement C3 vs C5 inhibition in severe covid-19: Early clinical findings reveal differential biological efficacy. Clin Immunol (2020) 220:108598. doi:&#xa0;10.1016/j.clim.2020.108598</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108598</ArticleId><ArticleId IdType="pmc">PMC7501834</ArticleId><ArticleId IdType="pubmed">32961333</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Gao Y, Zhou J, Shi Y, Xia D, Shen HM. Friend or foe? implication of the autophagy-lysosome pathway in sars-Cov-2 infection and covid-19. Int J Biol Sci (2022) 18(12):4690&#x2013;703. doi:&#xa0;10.7150/ijbs.72544</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.72544</ArticleId><ArticleId IdType="pmc">PMC9305279</ArticleId><ArticleId IdType="pubmed">35874956</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. . Characterization of spike glycoprotein of sars-Cov-2 on virus entry and its immune cross-reactivity with sars-cov. Nat Commun (2020) 11(1):1620. doi:&#xa0;10.1038/s41467-020-15562-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15562-9</ArticleId><ArticleId IdType="pmc">PMC7100515</ArticleId><ArticleId IdType="pubmed">32221306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. . Cryo-em structure of the 2019-ncov spike in the prefusion conformation. Science (2020) 367(6483):1260&#x2013;3. doi:&#xa0;10.1126/science.abb2507</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Zhao J, Liu S, Feng J, Luo Y, He X, et al. . Ace2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes sars-Cov-2 and its prevalent variants. Emerg Microbes Infect (2022) 11(1):1488&#x2013;99. doi:&#xa0;10.1080/22221751.2022.2079426</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2079426</ArticleId><ArticleId IdType="pmc">PMC9176695</ArticleId><ArticleId IdType="pubmed">35587428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankerhold J, Giese S, Kolb P, Maul-Pavicic A, G&#xf6;ppert N, Ciminski K, et al. . Circulating immune complexes drive immunopathology in covid-19. bioRxiv (2021) 13(1):5654. doi: 10.1101/2021.06.25.449893</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.25.449893</ArticleId><ArticleId IdType="pmc">PMC9513013</ArticleId><ArticleId IdType="pubmed">36163132</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. . Covid-19 vaccine effectiveness in new York state. N Engl J Med (2022) 386(2):116&#x2013;27. doi:&#xa0;10.1056/NEJMoa2116063</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116063</ArticleId><ArticleId IdType="pmc">PMC8693697</ArticleId><ArticleId IdType="pubmed">34942067</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. . Effectiveness of covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med (2021) 385(15):1355&#x2013;71. doi:&#xa0;10.1056/NEJMoa2110362</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110362</ArticleId><ArticleId IdType="pmc">PMC8451184</ArticleId><ArticleId IdType="pubmed">34496194</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R, Kaki M, Potluri VS, Kahar P, Khanna D. A comprehensive review of sars-Cov-2 vaccines: Pfizer, moderna &amp; Johnson &amp; Johnson. Hum Vaccin Immunother (2022) 18(1):2002083. doi:&#xa0;10.1080/21645515.2021.2002083</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.2002083</ArticleId><ArticleId IdType="pmc">PMC8862159</ArticleId><ArticleId IdType="pubmed">35130825</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman GA, O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, et al. . Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of covid-19 over an 8-month period: A randomised, double-blind, placebo-controlled trial. Lancet Infect Dis (2022) 22(10):1444&#x2013;54. doi:&#xa0;10.1016/s1473-3099(22)00416-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(22)00416-9</ArticleId><ArticleId IdType="pmc">PMC9255947</ArticleId><ArticleId IdType="pubmed">35803290</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, et al. . Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of covid-19 (Tackle): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med (2022) 10(10):985&#x2013;96. doi:&#xa0;10.1016/s2213-2600(22)00180-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(22)00180-1</ArticleId><ArticleId IdType="pmc">PMC9173721</ArticleId><ArticleId IdType="pubmed">35688164</ArticleId></ArticleIdList></Reference><Reference><Citation>ACTIV-3&#x2013;Therapeutics for Inpatients with COVID-19 (TICO) Study Group . Tixagevimab-cilgavimab for treatment of patients hospitalised with covid-19: A randomised, double-blind, phase 3 trial. Lancet Respir Med (2022) 10(10):972&#x2013;84. doi:&#xa0;10.1016/s2213-2600(22)00215-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(22)00215-6</ArticleId><ArticleId IdType="pmc">PMC9270059</ArticleId><ArticleId IdType="pubmed">35817072</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda R, Fujita J, Konishi Y, Kazuma Y, Yamazaki H, Anzai I, et al. . A panel of nanobodies recognizing conserved hidden clefts of all sars-Cov-2 spike variants including omicron. Commun Biol (2022) 5(1):669. doi:&#xa0;10.1038/s42003-022-03630-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03630-3</ArticleId><ArticleId IdType="pmc">PMC9257560</ArticleId><ArticleId IdType="pubmed">35794202</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein JB, Bates TA, Leier HC, McBride SK, Barklis E, Tafesse FG. A potent alpaca-derived nanobody that neutralizes sars-Cov-2 variants. iScience (2022) 25(3):103960. doi:&#xa0;10.1016/j.isci.2022.103960</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.103960</ArticleId><ArticleId IdType="pmc">PMC8863326</ArticleId><ArticleId IdType="pubmed">35224467</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B, Li S, Tabata T, Wang N, Cao L, Kumar GR, et al. . Accelerating perx reaction enables covalent nanobodies for potent neutralization of sars-Cov-2 and variants. Chem (2022) 8(10):2766&#x2013;83. doi:&#xa0;10.1101/2022.03.11.483867</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.11.483867</ArticleId><ArticleId IdType="pmc">PMC9288967</ArticleId><ArticleId IdType="pubmed">35874165</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J, Kwon HJ, Cachau R, Chen CZ, Butay KJ, Duan Z, et al. . Dromedary Camel Nanobodies Broadly Neutralize Sars-Cov-2 Variants. Proc Natl Acad Sci USA (2022) 119(18):e2201433119. doi:&#xa0;10.1073/pnas.2201433119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2201433119</ArticleId><ArticleId IdType="pmc">PMC9170159</ArticleId><ArticleId IdType="pubmed">35476528</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ttler T, Aksu M, Dickmanns A, Stegmann KM, Gregor K, Rees R, et al. . Neutralization of sars-Cov-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. EMBO J (2021) 40(19):e107985. doi:&#xa0;10.15252/embj.2021107985</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021107985</ArticleId><ArticleId IdType="pmc">PMC8420576</ArticleId><ArticleId IdType="pubmed">34302370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Li S, Liu J, Chen J. Global trends in nursing-related research on covid-19: A bibliometric analysis. Front Public Health (2022) 10:933555. doi:&#xa0;10.3389/fpubh.2022.933555</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.933555</ArticleId><ArticleId IdType="pmc">PMC9339968</ArticleId><ArticleId IdType="pubmed">35923953</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Li Z, Guo J, Yang Y, Liu C, Wang M, et al. . The hotspots and trends of coronavirus disease 2019 (Covid-19) and physical therapy: A bibliometric and visual analysis. J Phys Ther Sci (2021) 33(12):903&#x2013;7. doi:&#xa0;10.1589/jpts.33.903</Citation><ArticleIdList><ArticleId IdType="doi">10.1589/jpts.33.903</ArticleId><ArticleId IdType="pmc">PMC8636920</ArticleId><ArticleId IdType="pubmed">34873371</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, Yao R, Wang S, Chen G, Wang Y. Mapping trends and hotspots regarding clinical research on covid-19: A bibliometric analysis of global research. Front Public Health (2021) 9:713487. doi:&#xa0;10.3389/fpubh.2021.713487</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.713487</ArticleId><ArticleId IdType="pmc">PMC8419357</ArticleId><ArticleId IdType="pubmed">34497794</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Tena MA, Martinez-Perez C, Villa-Collar C, Alvarez-Peregrina C. Impact of covid-19 at the ocular level: A citation network study. J Clin Med (2021) 10(7):1340. doi:&#xa0;10.3390/jcm10071340</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10071340</ArticleId><ArticleId IdType="pmc">PMC8036864</ArticleId><ArticleId IdType="pubmed">33804977</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng K, Guo Q, Yang W, Wang Y, Sun Z, Wu H. Mapping knowledge landscapes and emerging trends of the links between bone metabolism and diabetes mellitus: A bibliometric analysis from 2000 to 2021. Front Public Health (2022) 10:918483. doi:&#xa0;10.3389/fpubh.2022.918483</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.918483</ArticleId><ArticleId IdType="pmc">PMC9204186</ArticleId><ArticleId IdType="pubmed">35719662</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Leydesdorff L. Patterns of connections and movements in dual-map overlays: A new method of publication portfolio analysis. J Assoc Inf Sci Technol (2014) 65(2):334&#x2013;51. doi:&#xa0;10.1002/asi.22968</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/asi.22968</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Z, Xu S, Wu X, Hu R, Li H, He H, et al. . Knowledge mapping of multicriteria decision analysis in healthcare: A bibliometric analysis. Front Public Health (2022) 10:895552. doi:&#xa0;10.3389/fpubh.2022.895552</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.895552</ArticleId><ArticleId IdType="pmc">PMC9218106</ArticleId><ArticleId IdType="pubmed">35757629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao JJ, Yuan Q, Wang HY, Liu W, Liao XJ, Su YY, et al. . Antibody responses to sars-Cov-2 in patients with novel coronavirus disease 2019. Clin Infect Dis (2020) 71(16):2027&#x2013;34. doi:&#xa0;10.1093/cid/ciaa344</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa344</ArticleId><ArticleId IdType="pmc">PMC7184337</ArticleId><ArticleId IdType="pubmed">32221519</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C, Zhou LQ, Hu ZW, Zhang SQ, Yang S, Tao Y, et al. . Dysregulation of immune response in patients with coronavirus 2019 (Covid-19) in wuhan, China. Clin Infect Dis (2020) 71(15):762&#x2013;8. doi:&#xa0;10.1093/cid/ciaa248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa248</ArticleId><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan SF, et al. . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting wuhan. Emerging Microbes Infections (2020) 9(1):221&#x2013;36. doi:&#xa0;10.1080/22221751.2020.1719902</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1719902</ArticleId><ArticleId IdType="pmc">PMC7067204</ArticleId><ArticleId IdType="pubmed">31987001</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao XT, Ye F, Zhang M, Cui C, Huang BY, Niu PH, et al. . In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (Sars-Cov-2). Clin Infect Dis (2020) 71(15):732&#x2013;9. doi:&#xa0;10.1093/cid/ciaa237</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa237</ArticleId><ArticleId IdType="pmc">PMC7108130</ArticleId><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CY, Pan RY, Wan XY, Tan YL, Xu LK, McIntyre RS, et al. . A longitudinal study on the mental health of general population during the covid-19 epidemic in China. Brain Behav And Immun (2020) 87:40&#x2013;8. doi:&#xa0;10.1016/j.bbi.2020.04.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.04.028</ArticleId><ArticleId IdType="pmc">PMC7153528</ArticleId><ArticleId IdType="pubmed">32298802</ArticleId></ArticleIdList></Reference><Reference><Citation>To KKW, Tsang OTY, Yip CCY, Chan KH, Wu TC, Chan JMC, et al. . Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis (2020) 71(15):841&#x2013;3. doi:&#xa0;10.1093/cid/ciaa149</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa149</ArticleId><ArticleId IdType="pmc">PMC7108139</ArticleId><ArticleId IdType="pubmed">32047895</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. . Molecular and serological investigation of 2019-ncov infected patients: Implication of multiple shedding routes. Emerging Microbes Infections (2020) 9(1):386&#x2013;89. doi:&#xa0;10.1080/22221751.2020.1729071</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1729071</ArticleId><ArticleId IdType="pmc">PMC7048229</ArticleId><ArticleId IdType="pubmed">32065057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YS, Xu XL, Chen ZJ, Duan JH, Hashimoto K, Yang L, et al. . Nervous system involvement after infection with covid-19 and other coronaviruses. Brain Behav And Immun (2020) 87:18&#x2013;22. doi:&#xa0;10.1016/j.bbi.2020.03.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.03.031</ArticleId><ArticleId IdType="pmc">PMC7146689</ArticleId><ArticleId IdType="pubmed">32240762</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Ren LL, Yang SY, Xiao M, Chang D, Yang F, et al. . Profiling early humoral response to diagnose novel coronavirus disease (Covid-19). Clin Infect Dis (2020) 71(15):778&#x2013;85. doi:&#xa0;10.1093/cid/ciaa310</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa310</ArticleId><ArticleId IdType="pmc">PMC7184472</ArticleId><ArticleId IdType="pubmed">32198501</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai WB, He L, Zhang XJ, Pu J, Voronin D, Jiang SB, et al. . Characterization of the receptor-binding domain (Rbd) of 2019 novel coronavirus: Implication for development of rbd protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol (2020) 17(6):613&#x2013;20. doi:&#xa0;10.1038/s41423-020-0400-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0400-4</ArticleId><ArticleId IdType="pmc">PMC7091888</ArticleId><ArticleId IdType="pubmed">32203189</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium WHOST . Repurposed antiviral drugs for covid-19-Interim who solidarity trial results. New Engl J Of Med (2021) 384(6):497&#x2013;511. doi:&#xa0;10.1056/NEJMoa2023184</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. . Association between administration of systemic corticosteroids and mortality among critically ill patients with covid-19 a meta-analysis. Jama-Journal Of Am Med Assoc (2020) 324(13):1330&#x2013;41. doi:&#xa0;10.1001/jama.2020.17023</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17023</ArticleId><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates A, Warren KT, Henderson C, McPherson M, Obubah O, Graaff P, et al. . The world health organization's frontline support to countries during the covid-19 pandemic in 2020. Front Public Health (2022) 10:850260. doi:&#xa0;10.3389/fpubh.2022.850260</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.850260</ArticleId><ArticleId IdType="pmc">PMC8971552</ArticleId><ArticleId IdType="pubmed">35372256</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Kochhar S, Wolff J, Atuire C, Bhan A, Emanuel E, et al. . Who guidance on covid-19 vaccine trial designs in the context of authorized covid-19 vaccines and expanding global access: Ethical considerations. Vaccine (2022) 40(14):2140&#x2013;9. doi:&#xa0;10.1016/j.vaccine.2022.02.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.038</ArticleId><ArticleId IdType="pmc">PMC8882397</ArticleId><ArticleId IdType="pubmed">35248422</ArticleId></ArticleIdList></Reference><Reference><Citation>Knezevic I, Mattiuzzo G, Page M, Minor P, Griffiths E, Nuebling M, et al. . Who international standard for evaluation of the antibody response to covid-19 vaccines: Call for urgent action by the scientific community. Lancet Microbe (2022) 3(3):e235&#x2013;e40. doi:&#xa0;10.1016/s2666-5247(21)00266-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2666-5247(21)00266-4</ArticleId><ArticleId IdType="pmc">PMC8547804</ArticleId><ArticleId IdType="pubmed">34723229</ArticleId></ArticleIdList></Reference><Reference><Citation>Badu K, Oyebola K, Zahouli JZB, Fagbamigbe AF, de Souza DK, Dukhi N, et al. . Sars-Cov-2 viral shedding and transmission dynamics: Implications of who covid-19 discharge guidelines. Front Med (Lausanne) (2021) 8:648660. doi:&#xa0;10.3389/fmed.2021.648660</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.648660</ArticleId><ArticleId IdType="pmc">PMC8259580</ArticleId><ArticleId IdType="pubmed">34239886</ArticleId></ArticleIdList></Reference><Reference><Citation>Who Guidelines Approved by the Guidelines Review Committee . Drugs to prevent covid-19: A who living guideline Vol. 2021. . Geneva: World Health Organization&#xa9;; (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">35917395</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngoy N, Oyugi B, Ouma PO, Conteh IN, Woldetsadik SF, Nanyunja M, et al. . Coordination mechanisms for covid-19 in the who regional office for Africa. BMC Health Serv Res (2022) 22(1):711. doi:&#xa0;10.1186/s12913-022-08035-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-022-08035-w</ArticleId><ArticleId IdType="pmc">PMC9142827</ArticleId><ArticleId IdType="pubmed">35643550</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CL, Wang YM, Li XW, Ren LL, Zhao JP, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in wuhan, China. Lancet (2020) 395(10223):497&#x2013;506. doi:&#xa0;10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du RH, Fan GH, Liu Y, Liu ZB, et al. . Clinical course and risk factors for mortality of adult inpatients with covid-19 in wuhan, China: A retrospective cohort study. LANCET (2020) 395(10229):1054&#x2013;62. doi:&#xa0;10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N, Zhang DY, Wang WL, Li XW, Yang B, Song JD, et al. . A novel coronavirus from patients with pneumonia in China, 2019. New Engl J Of Med (2020) 382(8):727&#x2013;33. doi:&#xa0;10.1056/NEJMoa2001017</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. . Clinical characteristics of coronavirus disease 2019 in China. New Engl J Of Med (2020) 382(18):1708&#x2013;20. doi:&#xa0;10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallam M. Covid-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates. VACCINES (2021) 9(2):160. doi:&#xa0;10.3390/vaccines9020160</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9020160</ArticleId><ArticleId IdType="pmc">PMC7920465</ArticleId><ArticleId IdType="pubmed">33669441</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B, Wang CH, Tan YJ, Chen XW, Liu Y, Ning LF, et al. . Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (Covid-19). Front In Immunol (2020) 11:827. doi:&#xa0;10.3389/fimmu.2020.00827</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00827</ArticleId><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter PL, Pennell ML, Katz ML. Acceptability of a covid-19 vaccine among adults in the united states: How many people would get vaccinated? Vaccine (2020) 38(42):6500&#x2013;7. doi:&#xa0;10.1016/j.vaccine.2020.08.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.08.043</ArticleId><ArticleId IdType="pmc">PMC7440153</ArticleId><ArticleId IdType="pubmed">32863069</ArticleId></ArticleIdList></Reference><Reference><Citation>Detoc M, Bruel S, Frappe P, Tardy B, Botelho-Nevers E, Gagneux-Brunon A. Intention to participate in a covid-19 vaccine clinical trial and to get vaccinated against covid-19 in France during the pandemic. Vaccine (2020) 38(45):7002&#x2013;6. doi:&#xa0;10.1016/j.vaccine.2020.09.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.09.041</ArticleId><ArticleId IdType="pmc">PMC7498238</ArticleId><ArticleId IdType="pubmed">32988688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz JB, Bell RA. Predictors of intention to vaccinate against covid-19: Results of a nationwide survey. Vaccine (2021) 39(7):1080&#x2013;6. doi:&#xa0;10.1016/j.vaccine.2021.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.01.010</ArticleId><ArticleId IdType="pmc">PMC7794597</ArticleId><ArticleId IdType="pubmed">33461833</ArticleId></ArticleIdList></Reference><Reference><Citation>Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. . Evidence for antibody as a protective correlate for covid-19 vaccines. Vaccine (2021) 39(32):4423&#x2013;8. doi:&#xa0;10.1016/j.vaccine.2021.05.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.063</ArticleId><ArticleId IdType="pmc">PMC8142841</ArticleId><ArticleId IdType="pubmed">34210573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang KL, Wong ELY, Ho KF, Cheung AWL, Chan EYY, Yeoh EK, et al. . Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey. VACCINE (2020) 38(45):7049&#x2013;56. doi:&#xa0;10.1016/j.vaccine.2020.09.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.09.021</ArticleId><ArticleId IdType="pmc">PMC7834255</ArticleId><ArticleId IdType="pubmed">32980199</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong MCS, Wong ELY, Huang JJ, Cheung AWL, Law K, Chong MKC, et al. . Acceptance of the covid-19 vaccine based on the health belief model: A population-based survey in Hong Kong. VACCINE (2021) 39(7):1148&#x2013;56. doi:&#xa0;10.1016/j.vaccine.2020.12.083</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.12.083</ArticleId><ArticleId IdType="pmc">PMC7832076</ArticleId><ArticleId IdType="pubmed">33461834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Li D, Huang X, Luo Q, Li X, Zhang X, et al. . A bibliometric analysis and visualization of photothermal therapy on cancer. Transl Cancer Res (2021) 10(3):1204&#x2013;15. doi:&#xa0;10.21037/tcr-20-2961</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tcr-20-2961</ArticleId><ArticleId IdType="pmc">PMC8797757</ArticleId><ArticleId IdType="pubmed">35116448</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Yang L, Mao H, Ma F, Wang Y, Zhan Y. Knowledge domain and emerging trends in podocyte injury research from 1994 to 2021: A bibliometric and visualized analysis. Front Pharmacol (2021) 12:772386. doi:&#xa0;10.3389/fphar.2021.772386</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.772386</ArticleId><ArticleId IdType="pmc">PMC8678497</ArticleId><ArticleId IdType="pubmed">34925030</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. . Reduced neutralization of sars-Cov-2 B.1.617 by vaccine and convalescent serum. Cell (2021) 184(16):4220&#x2013;36.e13. doi:&#xa0;10.1016/j.cell.2021.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.06.020</ArticleId><ArticleId IdType="pmc">PMC8218332</ArticleId><ArticleId IdType="pubmed">34242578</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang B, Zhang Y, Ling Q, Xie Z, Li N, Wu D. Characteristics and management of sars-Cov-2 delta variant-induced covid-19 infections from may to October 2021 in China: Post-vaccination infection cases. Am J Transl Res (2022) 14(6):3603&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9274556</ArticleId><ArticleId IdType="pubmed">35836857</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez DR, Sch&#xe4;fer A, Leist SR, de la Cruz G, West A, Atochina-Vasserman EN, et al. . Chimeric spike mrna vaccines protect against sarbecovirus challenge in mice. Science (2021) 373(6558):991&#x2013;8. doi:&#xa0;10.1126/science.abi4506</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abi4506</ArticleId><ArticleId IdType="pmc">PMC8899822</ArticleId><ArticleId IdType="pubmed">34214046</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawalagatti V, Kirthika P, Hewawaduge C, Yang MS, Park JY, Oh B, et al. . Bacteria-enabled oral delivery of a replicon-based mrna vaccine candidate protects against ancestral and delta variant sars-Cov-2. Mol Ther (2022) 30(5):1926&#x2013;40. doi:&#xa0;10.1016/j.ymthe.2022.01.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.01.042</ArticleId><ArticleId IdType="pmc">PMC8810265</ArticleId><ArticleId IdType="pubmed">35123065</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization . Classification of omicron (B. 1.1. 529): Sars-Cov-2 variant of concern. Available at: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern (Accessed November 26, 2021)</Citation></Reference><Reference><Citation>Kumar S, Karuppanan K, Subramaniam G. Omicron (Ba.1) and Sub-variants (Ba.1.1, Ba.2, and Ba.3) of sars-Cov-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment. J Med Virol (2022) 94(10):4780&#x2013;91. doi:&#xa0;10.1002/jmv.27927</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27927</ArticleId><ArticleId IdType="pmc">PMC9347785</ArticleId><ArticleId IdType="pubmed">35680610</ArticleId></ArticleIdList></Reference><Reference><Citation>Setiabudi D, Sribudiani Y, Hermawan K, Andriyoko B, Nataprawira HM. The omicron variant of concern: The genomics, diagnostics, and clinical characteristics in children. Front Pediatr (2022) 10:898463. doi:&#xa0;10.3389/fped.2022.898463</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.898463</ArticleId><ArticleId IdType="pmc">PMC9378986</ArticleId><ArticleId IdType="pubmed">35983081</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the sars-Cov-2 omicron variants Ba.1 to Ba.5: Implications for immune escape and transmission. Rev Med Virol (2022) 32(5):e2381. doi:&#xa0;10.1002/rmv.2381</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2381</ArticleId><ArticleId IdType="pmc">PMC9349777</ArticleId><ArticleId IdType="pubmed">35856385</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, et al. . Antibody evasion properties of sars-Cov-2 omicron sublineages. Nature (2022) 604(7906):553&#x2013;6. doi:&#xa0;10.1038/s41586-022-04594-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04594-4</ArticleId><ArticleId IdType="pmc">PMC9021018</ArticleId><ArticleId IdType="pubmed">35240676</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al. . Omicron Ba.4/Ba.5 escape neutralizing immunity elicited by Ba.1 infection. Nat Commun (2022) 13(1):4686. doi:&#xa0;10.1038/s41467-022-32396-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32396-9</ArticleId><ArticleId IdType="pmc">PMC9364294</ArticleId><ArticleId IdType="pubmed">35948557</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, et al. . Ba.2.12.1, Ba.4 and Ba.5 escape antibodies elicited by omicron infection. Nature (2022) 608(7923):593&#x2013;602. doi:&#xa0;10.1038/s41586-022-04980-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcotte H, Hammarstr&#xf6;m L, Pan-Hammarstr&#xf6;m Q. Limited cross-variant neutralization after primary omicron infection: Consideration for a variant-containing booster. Signal Transduct Target Ther (2022) 7(1):294. doi:&#xa0;10.1038/s41392-022-01146-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01146-0</ArticleId><ArticleId IdType="pmc">PMC9395412</ArticleId><ArticleId IdType="pubmed">35995763</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. . Neutralizing antibody levels are highly predictive of immune protection from symptomatic sars-Cov-2 infection. Nat Med (2021) 27(7):1205&#x2013;11. doi:&#xa0;10.1038/s41591-021-01377-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. . Considerable escape of sars-Cov-2 omicron to antibody neutralization. Nature (2022) 602(7898):671&#x2013;5. doi:&#xa0;10.1038/s41586-021-04389-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J, Xie X, Liu M, Shi PY, Ren P. Neutralization titers in vaccinated patients with sars-Cov-2 delta breakthrough infections. mBio (2022) 13(4):e0199622. doi:&#xa0;10.1128/mbio.01996-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.01996-22</ArticleId><ArticleId IdType="pmc">PMC9426493</ArticleId><ArticleId IdType="pubmed">35924850</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Han J, Zhang Y, He J, Yu W, Zhang X, et al. . Sars-Cov-2 omicron variant: Epidemiological features, biological characteristics, and clinical significance. Front Immunol (2022) 13:877101. doi:&#xa0;10.3389/fimmu.2022.877101</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.877101</ArticleId><ArticleId IdType="pmc">PMC9099228</ArticleId><ArticleId IdType="pubmed">35572518</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Zheng A, Li D, Zhang R, Sun H, Wang Q, et al. . Neutralisation of Zf2001-elicited antisera to sars-Cov-2 variants. Lancet Microbe (2021) 2(10):e494. doi:&#xa0;10.1016/s2666-5247(21)00217-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2666-5247(21)00217-2</ArticleId><ArticleId IdType="pmc">PMC8378832</ArticleId><ArticleId IdType="pubmed">34458880</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Peng P, Cao X, Wu K, Chen J, Wang K, et al. . Increased immune escape of the new sars-Cov-2 variant of concern omicron. Cell Mol Immunol (2022) 19(2):293&#x2013;5. doi:&#xa0;10.1038/s41423-021-00836-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00836-z</ArticleId><ArticleId IdType="pmc">PMC8749347</ArticleId><ArticleId IdType="pubmed">35017716</ArticleId></ArticleIdList></Reference><Reference><Citation>Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of Bnt162b2 vaccine against omicron variant in south Africa. N Engl J Med (2022) 386(5):494&#x2013;6. doi:&#xa0;10.1056/NEJMc2119270</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119270</ArticleId><ArticleId IdType="pmc">PMC8757569</ArticleId><ArticleId IdType="pubmed">34965358</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C, et al. . Third Bnt162b2 vaccination neutralization of sars-Cov-2 omicron infection. N Engl J Med (2022) 386(5):492&#x2013;4. doi:&#xa0;10.1056/NEJMc2119358</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119358</ArticleId><ArticleId IdType="pmc">PMC8823651</ArticleId><ArticleId IdType="pubmed">34965337</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M, et al. . Homologous or heterologous booster of inactivated vaccine reduces sars-Cov-2 omicron variant escape from neutralizing antibodies. Emerg Microbes Infect (2022) 11(1):477&#x2013;81. doi:&#xa0;10.1080/22221751.2022.2030200</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2030200</ArticleId><ArticleId IdType="pmc">PMC8820826</ArticleId><ArticleId IdType="pubmed">35034583</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. . Mrna-based covid-19 vaccine boosters induce neutralizing immunity against sars-Cov-2 omicron variant. Cell (2022) 185(3):457&#x2013;66.e4. doi:&#xa0;10.1016/j.cell.2021.12.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.033</ArticleId><ArticleId IdType="pmc">PMC8733787</ArticleId><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, et al. . Sars-Cov-2 omicron variant neutralization after mrna-1273 booster vaccination. N Engl J Med (2022) 386(11):1088&#x2013;91. doi:&#xa0;10.1056/NEJMc2119912</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119912</ArticleId><ArticleId IdType="pmc">PMC8809504</ArticleId><ArticleId IdType="pubmed">35081298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J, et al. . Omicron variant showed lower neutralizing sensitivity than other sars-Cov-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect (2022) 11(1):337&#x2013;43. doi:&#xa0;10.1080/22221751.2021.2022440</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2022440</ArticleId><ArticleId IdType="pmc">PMC8788341</ArticleId><ArticleId IdType="pubmed">34935594</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, et al. . Deep immune profiling of covid-19 patients reveals distinct immunotypes with therapeutic implications. Science (2020) 369(6508):eabc8511. doi:&#xa0;10.1126/science.abc8511</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc8511</ArticleId><ArticleId IdType="pmc">PMC7402624</ArticleId><ArticleId IdType="pubmed">32669297</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. . Complex immune dysregulation in covid-19 patients with severe respiratory failure. Cell Host Microbe (2020) 27(6):992&#x2013;1000.e3. doi:&#xa0;10.1016/j.chom.2020.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, et al. . Heightened innate immune responses in the respiratory tract of covid-19 patients. Cell Host Microbe (2020) 27(6):883&#x2013;90.e2. doi:&#xa0;10.1016/j.chom.2020.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7196896</ArticleId><ArticleId IdType="pubmed">32407669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. . Longitudinal analyses reveal immunological misfiring in severe covid-19. Nature (2020) 584(7821):463&#x2013;9. doi:&#xa0;10.1038/s41586-020-2588-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR, et al. . Comprehensive mapping of immune perturbations associated with severe covid-19. Sci Immunol (2020) 5(49):eabd7114. doi:&#xa0;10.1126/sciimmunol.abd7114</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd7114</ArticleId><ArticleId IdType="pmc">PMC7402634</ArticleId><ArticleId IdType="pubmed">32669287</ArticleId></ArticleIdList></Reference><Reference><Citation>Seder RA, Ahmed R. Similarities and differences in Cd4+ and Cd8+ effector and memory T cell generation. Nat Immunol (2003) 4(9):835&#x2013;42. doi:&#xa0;10.1038/ni969</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni969</ArticleId><ArticleId IdType="pubmed">12942084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosaki T, Kometani K, Ise W. Memory b cells. Nat Rev Immunol (2015) 15(3):149&#x2013;59. doi:&#xa0;10.1038/nri3802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3802</ArticleId><ArticleId IdType="pubmed">25677494</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, et al. . Delayed production of neutralizing antibodies correlates with fatal covid-19. Nat Med (2021) 27(7):1178&#x2013;86. doi:&#xa0;10.1038/s41591-021-01355-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01355-0</ArticleId><ArticleId IdType="pmc">PMC8785364</ArticleId><ArticleId IdType="pubmed">33953384</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, et al. . Early induction of functional sars-Cov-2-Specific T cells associates with rapid viral clearance and mild disease in covid-19 patients. Cell Rep (2021) 34(6):108728. doi:&#xa0;10.1016/j.celrep.2021.108728</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108728</ArticleId><ArticleId IdType="pmc">PMC7826084</ArticleId><ArticleId IdType="pubmed">33516277</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. . Antigen-specific adaptive immunity to sars-Cov-2 in acute covid-19 and associations with age and disease severity. Cell (2020) 183(4):996&#x2013;1012.e19. doi:&#xa0;10.1016/j.cell.2020.09.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Crotty S. Adaptive immunity to sars-Cov-2 and covid-19. Cell (2021) 184(4):861&#x2013;80. doi:&#xa0;10.1016/j.cell.2021.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to sars-Cov-2. Nat Rev Immunol (2020) 20(11):709&#x2013;13. doi:&#xa0;10.1038/s41577-020-00460-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00460-4</ArticleId><ArticleId IdType="pmc">PMC7537578</ArticleId><ArticleId IdType="pubmed">33024281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoletti A, Le Bert N, Qui M, Tan AT. Sars-Cov-2-Specific T cells in infection and vaccination. Cell Mol Immunol (2021) 18(10):2307&#x2013;12. doi:&#xa0;10.1038/s41423-021-00743-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00743-3</ArticleId><ArticleId IdType="pmc">PMC8408362</ArticleId><ArticleId IdType="pubmed">34471260</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. . Correlates of protection against sars-Cov-2 in rhesus macaques. Nature (2021) 590(7847):630&#x2013;4. doi:&#xa0;10.1038/s41586-020-03041-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03041-6</ArticleId><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. . Single-cell landscape of bronchoalveolar immune cells in patients with covid-19. Nat Med (2020) 26(6):842&#x2013;4. doi:&#xa0;10.1038/s41591-020-0901-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, Str&#xe5;lin K, Gorin JB, Olsson A, et al. . Robust T cell immunity in convalescent individuals with asymptomatic or mild covid-19. Cell (2020) 183(1):158&#x2013;68.e14. doi:&#xa0;10.1016/j.cell.2020.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, et al. . Rapid induction of antigen-specific Cd4(+) T cells is associated with coordinated humoral and cellular immunity to sars-Cov-2 mrna vaccination. Immunity (2021) 54(9):2133&#x2013;42.e3. doi:&#xa0;10.1016/j.immuni.2021.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.08.001</ArticleId><ArticleId IdType="pmc">PMC8361141</ArticleId><ArticleId IdType="pubmed">34453880</ArticleId></ArticleIdList></Reference><Reference><Citation>Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. . Cd8(+) T cells contribute to survival in patients with covid-19 and hematologic cancer. Nat Med (2021) 27(7):1280&#x2013;9. doi:&#xa0;10.1038/s41591-021-01386-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01386-7</ArticleId><ArticleId IdType="pmc">PMC8291091</ArticleId><ArticleId IdType="pubmed">34017137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Tian Q, Ye L. The differentiation and maintenance of sars-Cov-2-Specific follicular helper T cells. Front Cell Infect Microbiol (2022) 12:953022. doi:&#xa0;10.3389/fcimb.2022.953022</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.953022</ArticleId><ArticleId IdType="pmc">PMC9329515</ArticleId><ArticleId IdType="pubmed">35909969</ArticleId></ArticleIdList></Reference><Reference><Citation>Niessl J, Sekine T. Buggert m. T Cell Immun to Sars-Cov-2. Semin Immunol (2021) 55:101505. doi:&#xa0;10.1016/j.smim.2021.101505</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2021.101505</ArticleId><ArticleId IdType="pmc">PMC8529278</ArticleId><ArticleId IdType="pubmed">34711489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent SJ, Khoury DS, Reynaldi A, Juno JA, Wheatley AK, Stadler E, et al. . Disentangling the relative importance of T cell responses in covid-19: Leading actors or supporting cast? Nat Rev Immunol (2022) 22(6):387&#x2013;97. doi:&#xa0;10.1038/s41577-022-00716-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00716-1</ArticleId><ArticleId IdType="pmc">PMC9047577</ArticleId><ArticleId IdType="pubmed">35484322</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA . (Accessed August 7, 2022).</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and efficacy of the Bnt162b2 mrna covid-19 vaccine. N Engl J Med (2020) 383(27):2603&#x2013;15. doi:&#xa0;10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SJ, Moreira ED, Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and efficacy of the Bnt162b2 mrna covid-19 vaccine through 6 months. N Engl J Med (2021) 385(19):1761&#x2013;73. doi:&#xa0;10.1056/NEJMoa2110345</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110345</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck RW, Jr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. . Safety, immunogenicity, and efficacy of the Bnt162b2 covid-19 vaccine in adolescents. N Engl J Med (2021) 385(3):239&#x2013;50. doi:&#xa0;10.1056/NEJMoa2107456</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107456</ArticleId><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. . Safety and immunogenicity of seven covid-19 vaccines as a third dose (Booster) following two doses of Chadox1 ncov-19 or Bnt162b2 in the uk (Cov-boost): A blinded, multicentre, randomised, controlled, phase 2 trial. Lancet (2021) 398(10318):2258&#x2013;76. doi:&#xa0;10.1016/s0140-6736(21)02717-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)02717-3</ArticleId><ArticleId IdType="pmc">PMC8639161</ArticleId><ArticleId IdType="pubmed">34863358</ArticleId></ArticleIdList></Reference><Reference><Citation>Gro&#xdf; R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. . Heterologous Chadox1 ncov-19 and Bnt162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent sars-Cov-2 variants. EBioMedicine (2022) 75:103761. doi:&#xa0;10.1016/j.ebiom.2021.103761</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103761</ArticleId><ArticleId IdType="pmc">PMC8682749</ArticleId><ArticleId IdType="pubmed">34929493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. . Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med (2021) 385(7):585&#x2013;94. doi:&#xa0;10.1056/NEJMoa2108891</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108891</ArticleId><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the Bnt162b2 covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med (2021) 385(2):187&#x2013;9. doi:&#xa0;10.1056/NEJMc2104974</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2104974</ArticleId><ArticleId IdType="pmc">PMC8117967</ArticleId><ArticleId IdType="pubmed">33951357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, et al. . Safety and efficacy of the mrna Bnt162b2 vaccine against sars-Cov-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine (2021) 74:103705. doi:&#xa0;10.1016/j.ebiom.2021.103705</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103705</ArticleId><ArticleId IdType="pmc">PMC8629680</ArticleId><ArticleId IdType="pubmed">34861491</ArticleId></ArticleIdList></Reference><Reference><Citation>Firinu D, Perra A, Campagna M, Littera R, Fenu G, Meloni F, et al. . Evaluation of antibody response to Bnt162b2 mrna covid-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Clin Exp Med (2022) 22(3):477&#x2013;85. doi:&#xa0;10.1007/s10238-021-00771-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-021-00771-3</ArticleId><ArticleId IdType="pmc">PMC8570239</ArticleId><ArticleId IdType="pubmed">34741188</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyon Q, Sterlin D, Miyara M, Anna F, Mathian A, Lhote R, et al. . Bnt162b2 vaccine-induced humoral and cellular responses against sars-Cov-2 variants in systemic lupus erythematosus. Ann Rheum Dis (2022) 81(4):575&#x2013;83. doi:&#xa0;10.1136/annrheumdis-2021-221097</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221097</ArticleId><ArticleId IdType="pmc">PMC8494536</ArticleId><ArticleId IdType="pubmed">34607791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Planas D, Ouedrani A, Buffier S, Delage L, Nguyen Y, et al. . Immunogenicity of Bnt162b2 vaccine against the alpha and delta variants in immunocompromised patients with systemic inflammatory diseases. Ann Rheum Dis (2022) 81(5):720&#x2013;8. doi:&#xa0;10.1136/annrheumdis-2021-221508</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221508</ArticleId><ArticleId IdType="pubmed">35022159</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, et al. . Immunogenicity and safety of the Bnt162b2 mrna covid-19 vaccine in people living with hiv-1. Clin Microbiol Infect (2021) 27(12):1851&#x2013;5. doi:&#xa0;10.1016/j.cmi.2021.07.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.07.031</ArticleId><ArticleId IdType="pmc">PMC8382485</ArticleId><ArticleId IdType="pubmed">34438069</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueda-Fern&#xe1;ndez M, Melguizo-Rodr&#xed;guez L, Costela-Ruiz VJ, Gonz&#xe1;lez-Acedo A, Ramos-Torrecillas J, Illescas-Montes R. The current status of covid-19 vaccines. a scoping review. Drug Discovery Today (2022) 27(11):103336. doi:&#xa0;10.1016/j.drudis.2022.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2022.08.004</ArticleId><ArticleId IdType="pmc">PMC9389839</ArticleId><ArticleId IdType="pubmed">35995361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The covid-19 cytokine storm; what we know so far. Front Immunol (2020) 11:1446. doi:&#xa0;10.3389/fimmu.2020.01446</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01446</ArticleId><ArticleId IdType="pmc">PMC7308649</ArticleId><ArticleId IdType="pubmed">32612617</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajjela BK, Zhou MM. Calming the cytokine storm of covid-19 through inhibition of Jak2/Stat3 signaling. Drug Discovery Today (2022) 27(2):390&#x2013;400. doi:&#xa0;10.1016/j.drudis.2021.10.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2021.10.016</ArticleId><ArticleId IdType="pmc">PMC8553370</ArticleId><ArticleId IdType="pubmed">34743903</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in covid-19. Signal Transduct Target Ther (2021) 6(1):255. doi:&#xa0;10.1038/s41392-021-00679-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00679-0</ArticleId><ArticleId IdType="pmc">PMC8261820</ArticleId><ArticleId IdType="pubmed">34234112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekele Y, Sui Y, Berzofsky JA. Il-7 in sars-Cov-2 infection and as a potential vaccine adjuvant. Front Immunol (2021) 12:737406. doi:&#xa0;10.3389/fimmu.2021.737406</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.737406</ArticleId><ArticleId IdType="pmc">PMC8484798</ArticleId><ArticleId IdType="pubmed">34603318</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva M, O'Garra A. The regulation of il-10 production by immune cells. Nat Rev Immunol (2010) 10(3):170&#x2013;81. doi:&#xa0;10.1038/nri2711</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2711</ArticleId><ArticleId IdType="pubmed">20154735</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T, Murakami M. Covid-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity (2020) 52(5):731&#x2013;3. doi:&#xa0;10.1016/j.immuni.2020.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7175868</ArticleId><ArticleId IdType="pubmed">32325025</ArticleId></ArticleIdList></Reference><Reference><Citation>Satarker S, Tom AA, Shaji RA, Alosious A, Luvis M, Nampoothiri M. Jak-stat pathway inhibition and their implications in covid-19 therapy. Postgrad Med (2021) 133(5):489&#x2013;507. doi:&#xa0;10.1080/00325481.2020.1855921</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00325481.2020.1855921</ArticleId><ArticleId IdType="pmc">PMC7784782</ArticleId><ArticleId IdType="pubmed">33245005</ArticleId></ArticleIdList></Reference><Reference><Citation>Nied&#x17a;wiedzka-Rystwej P, Majchrzak A, Kurkowska S, Ma&#x142;kowska P, Sierawska O, Hrynkiewicz R, et al. . Immune signature of covid-19: In-depth reasons and consequences of the cytokine storm. Int J Mol Sci (2022) 23(9):4545. doi:&#xa0;10.3390/ijms23094545</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23094545</ArticleId><ArticleId IdType="pmc">PMC9105989</ArticleId><ArticleId IdType="pubmed">35562935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiomi A, Usui T. Pivotal roles of gm-csf in autoimmunity and inflammation. Mediators Inflammation (2015) 2015:568543. doi:&#xa0;10.1155/2015/568543</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/568543</ArticleId><ArticleId IdType="pmc">PMC4370199</ArticleId><ArticleId IdType="pubmed">25838639</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter H, Kendall L, Boyd T, Sillau S, Bosco-Lauth A, Markham N, et al. . Gm-csf promotes immune response and survival in a mouse model of covid-19. Res Sq (2022). doi:&#xa0;10.21203/rs.3.rs-1213395/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1213395/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe covid-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents (2020) 55(5):105954. doi:&#xa0;10.1016/j.ijantimicag.2020.105954</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105954</ArticleId><ArticleId IdType="pmc">PMC7118634</ArticleId><ArticleId IdType="pubmed">32234467</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C. Tocilizumab: A therapeutic option for the treatment of cytokine storm syndrome in covid-19. Arch Med Res (2020) 51(6):595&#x2013;7. doi:&#xa0;10.1016/j.arcmed.2020.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC7241374</ArticleId><ArticleId IdType="pubmed">32482373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cure E, Kucuk A, Cure MC. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by covid-19, which is resistant to anakinra, tocilizumab, and janus kinase inhibitors. Indian J Pharmacol (2021) 53(3):226&#x2013;8. doi:&#xa0;10.4103/ijp.IJP_615_20</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijp.IJP_615_20</ArticleId><ArticleId IdType="pmc">PMC8262416</ArticleId><ArticleId IdType="pubmed">34169908</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S, Saxena B, Mehta P. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of covid-19. Heliyon (2021) 7(2):e06158. doi:&#xa0;10.1016/j.heliyon.2021.e06158</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2021.e06158</ArticleId><ArticleId IdType="pmc">PMC7846241</ArticleId><ArticleId IdType="pubmed">33553708</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese LH, Lenfant T, Calabrese C. Cytokine storm release syndrome and the prospects for immunotherapy with covid-19, part 4: The role of jak inhibition. Cleve Clin J Med (2021). doi:&#xa0;10.3949/ccjm.87a.ccc060</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.87a.ccc060</ArticleId><ArticleId IdType="pubmed">32847819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma VK, Prateeksha, Singh SP, Singh BN, Rao CV, Barik SK. Nanocurcumin potently inhibits sars-Cov-2 spike protein-induced cytokine storm by deactivation of Mapk/Nf-Kb signaling in epithelial cells. ACS Appl Bio Mater (2022) 5(2):483&#x2013;91. doi:&#xa0;10.1021/acsabm.1c00874</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsabm.1c00874</ArticleId><ArticleId IdType="pubmed">35112841</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirunavalli SK, Gourishetti K, Kotipalli RSS, Kuncha M, Kathirvel M, Kaur R, et al. . Dehydrozingerone ameliorates lipopolysaccharide induced acute respiratory distress syndrome by inhibiting cytokine storm, oxidative stress Via modulating the Mapk/Nf-Kb pathway. Phytomedicine (2021) 92:153729. doi:&#xa0;10.1016/j.phymed.2021.153729</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2021.153729</ArticleId><ArticleId IdType="pmc">PMC8390101</ArticleId><ArticleId IdType="pubmed">34517257</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryavanshi SV, Zaiachuk M, Pryimak N, Kovalchuk I, Kovalchuk O. Cannabinoids alleviate the lps-induced cytokine storm via attenuating Nlrp3 inflammasome signaling and Tyk2-mediated Stat3 signaling pathways in vitro. Cells (2022) 11(9):1391. doi:&#xa0;10.3390/cells11091391</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11091391</ArticleId><ArticleId IdType="pmc">PMC9103143</ArticleId><ArticleId IdType="pubmed">35563697</ArticleId></ArticleIdList></Reference><Reference><Citation>Manayi A, Nabavi SM, Khayatkashani M, Habtemariam S, Khayat Kashani HR. Arglabin could target inflammasome-induced Ards and cytokine storm associated with covid-19. Mol Biol Rep (2021) 48(12):8221&#x2013;5. doi:&#xa0;10.1007/s11033-021-06827-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-021-06827-7</ArticleId><ArticleId IdType="pmc">PMC8519322</ArticleId><ArticleId IdType="pubmed">34655016</ArticleId></ArticleIdList></Reference><Reference><Citation>Sly LM, Braun P, Woodcock BG. Covid-19: Cytokine storm Modulation/Blockade with oral polyvalent immunoglobulins (Pvig, Kmp01d): A potential and safe therapeutic agent (Primum nil nocere). Int J Clin Pharmacol Ther (2020) 58(12):678&#x2013;86. doi:&#xa0;10.5414/cp203890</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/cp203890</ArticleId><ArticleId IdType="pubmed">33141018</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinaro R, Pasto A, Taraballi F, Giordano F, Azzi JA, Tasciotti E, et al. . Biomimetic nanoparticles potentiate the anti-inflammatory properties of dexamethasone and reduce the cytokine storm syndrome: An additional weapon against covid-19? Nanomaterials (Basel) (2020) 10(11):2301. doi:&#xa0;10.3390/nano10112301</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano10112301</ArticleId><ArticleId IdType="pmc">PMC7699958</ArticleId><ArticleId IdType="pubmed">33233748</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, You J, Yang X, Wei Y, Zheng L, Zhao Y, et al. . Glycyrrhetinic acid: A potential drug for the treatment of covid-19 cytokine storm. Phytomedicine (2022) 102:154153. doi:&#xa0;10.1016/j.phymed.2022.154153</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2022.154153</ArticleId><ArticleId IdType="pmc">PMC9098921</ArticleId><ArticleId IdType="pubmed">35636166</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh YC, Doan LH, Huang ZY, Chu LW, Shi TH, Lee YR, et al. . Honeysuckle (Lonicera japonica) and huangqi (Astragalus membranaceus) suppress sars-Cov-2 entry and covid-19 related cytokine storm in vitro. Front Pharmacol (2021) 12:765553. doi:&#xa0;10.3389/fphar.2021.765553</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.765553</ArticleId><ArticleId IdType="pmc">PMC8990830</ArticleId><ArticleId IdType="pubmed">35401158</ArticleId></ArticleIdList></Reference><Reference><Citation>You J, Li H, Fan P, Yang X, Wei Y, Zheng L, et al. . Inspiration for covid-19 treatment: Network analysis and experimental validation of baicalin for cytokine storm. Front Pharmacol (2022) 13:853496. doi:&#xa0;10.3389/fphar.2022.853496</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.853496</ArticleId><ArticleId IdType="pmc">PMC8957998</ArticleId><ArticleId IdType="pubmed">35350754</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-acute covid-19 syndrome. Nat Med (2021) 27(4):601&#x2013;15. doi:&#xa0;10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of covid-19. Nature (2021) 594(7862):259&#x2013;64. doi:&#xa0;10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post covid-19 condition or long covid: A meta-analysis and systematic review. J Infect Dis (2022). doi:&#xa0;10.1093/infdis/jiac136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. . Characterizing long covid in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine (2021) 38:101019. doi:&#xa0;10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z, Altiery DEJV, Assoumou SA, Greenhalgh T. Long covid and health inequities: The role of primary care. Milbank Q (2021) 99(2):519&#x2013;41. doi:&#xa0;10.1111/1468-0009.12505</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1468-0009.12505</ArticleId><ArticleId IdType="pmc">PMC8241274</ArticleId><ArticleId IdType="pubmed">33783907</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F, Perego E. How and why patients made long covid. Soc Sci Med (2021) 268:113426. doi:&#xa0;10.1016/j.socscimed.2020.113426</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-Covid-19 condition by a Delphi consensus. Lancet Infect Dis (2022) 22(4):e102&#x2013;e7. doi:&#xa0;10.1016/s1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. . 'Long-covid': A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for covid-19. Thorax (2021) 76(4):396&#x2013;8. doi:&#xa0;10.1136/thoraxjnl-2020-215818</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, et al. . Multiorgan impairment in low-risk individuals with post-Covid-19 syndrome: A prospective, community-based study. BMJ Open (2021) 11(3):e048391. doi:&#xa0;10.1136/bmjopen-2020-048391</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al. . Autonomic dysfunction in 'Long covid': Rationale, physiology and management strategies. Clin Med (Lond) (2021) 21(1):e63&#x2013;e7. doi:&#xa0;10.7861/clinmed.2020-0896</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0896</ArticleId><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Tang N, Peluso MJ, Iyer NS, Torres L, Donatelli JL, et al. . Characterization and biomarker analyses of post-Covid-19 complications and neurological manifestations. Cells (2021) 10(2):386. doi:&#xa0;10.3390/cells10020386</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020386</ArticleId><ArticleId IdType="pmc">PMC7918597</ArticleId><ArticleId IdType="pubmed">33668514</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236&#x2009;379 survivors of covid-19: A retrospective cohort study using electronic health records. Lancet Psychiatry (2021) 8(5):416&#x2013;27. doi:&#xa0;10.1016/s2215-0366(21)00084-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuijt TJ, Lankelma JM, Scicluna BP, de Sousa e Melo F, Roelofs JJ, de Boer JD, et al. . The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut (2016) 65(4):575&#x2013;83. doi:&#xa0;10.1136/gutjnl-2015-309728</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-309728</ArticleId><ArticleId IdType="pmc">PMC4819612</ArticleId><ArticleId IdType="pubmed">26511795</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei M, Bose D, Nouri-Vaskeh M, Tajiknia V, Zand R, Ghasemi M. Long-term side effects and lingering symptoms post covid-19 recovery. Rev Med Virol (2022) 32(3):e2289. doi:&#xa0;10.1002/rmv.2289</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2289</ArticleId><ArticleId IdType="pmc">PMC8646420</ArticleId><ArticleId IdType="pubmed">34499784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumtaz A, Sheikh AAE, Khan AM, Khalid SN, Khan J, Nasrullah A, et al. . Covid-19 vaccine and long covid: A scoping review. Life (Basel) (2022) 12(7):1066. doi:&#xa0;10.3390/life12071066</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12071066</ArticleId><ArticleId IdType="pmc">PMC9324565</ArticleId><ArticleId IdType="pubmed">35888154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P, Gorelik Y, Zayyad H, Wertheim O, Wiegler KB, Jabal KA, et al. . Association between Bnt162b2 Vaccination and Reported Incidence of Post-Covid-19 Symptoms: Cross-Sectional Study 2020-21, Israel. npj Vaccines (2022) 7(1):101. doi:&#xa0;10.1101/2022.01.05.22268800</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.05.22268800</ArticleId><ArticleId IdType="pmc">PMC9411827</ArticleId><ArticleId IdType="pubmed">36028498</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. . Trajectory of long covid symptoms after covid-19 vaccination: Community based cohort study. Bmj (2022) 377:e069676. doi:&#xa0;10.1136/bmj-2021-069676</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisis SN, Durieux JC, Mouchati C, Perez JA, McComsey GA. The protective effect of coronavirus disease 2019 (Covid-19) vaccination on postacute sequelae of covid-19: A multicenter study from a Large national health research network. Open Forum Infect Dis (2022) 9(7):ofac228. doi:&#xa0;10.1093/ofid/ofac228</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac228</ArticleId><ArticleId IdType="pmc">PMC9129153</ArticleId><ArticleId IdType="pubmed">35818362</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with covid-19: An open-label, randomised, phase 2 trial. Lancet (2020) 395(10238):1695&#x2013;704. doi:&#xa0;10.1016/s0140-6736(20)31042-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)31042-4</ArticleId><ArticleId IdType="pmc">PMC7211500</ArticleId><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>Dastan F, Nadji SA, Saffaei A, Marjani M, Moniri A, Jamaati H, et al. . Subcutaneous administration of interferon beta-1a for covid-19: A non-controlled prospective trial. Int Immunopharmacol (2020) 85:106688. doi:&#xa0;10.1016/j.intimp.2020.106688</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106688</ArticleId><ArticleId IdType="pmc">PMC7275997</ArticleId><ArticleId IdType="pubmed">32544867</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (Il-6) blockade for coronavirus disease 2019 (Covid-19)-Induced cytokine release syndrome (Crs)? J Autoimmun (2020) 111:102452. doi:&#xa0;10.1016/j.jaut.2020.102452</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102452</ArticleId><ArticleId IdType="pmc">PMC7151347</ArticleId><ArticleId IdType="pubmed">32291137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah S, Abid R, Haider S, Khuda F, Albadrani GM, Abdulhakim JA, et al. . Assessment of tocilizumab (Humanized monoclonal antibody) for therapeutic efficacy and clinical safety in patients with coronavirus disease (Covid-19). Medicina (Kaunas) (2022) 58(8):1076. doi:&#xa0;10.3390/medicina58081076</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58081076</ArticleId><ArticleId IdType="pmc">PMC9412443</ArticleId><ArticleId IdType="pubmed">36013543</ArticleId></ArticleIdList></Reference><Reference><Citation>Murillo M, Lomiguen C, Terrell M, King A, Lin J, Ferretti S. Effect of sars Cov2-neutralizing monoclonal antibody on hospitalization and mortality in long-term care facility residents. Aging Dis (2022) 13(5):1523&#x2013;31. doi:&#xa0;10.14336/ad.2022.0205</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/ad.2022.0205</ArticleId><ArticleId IdType="pmc">PMC9466966</ArticleId><ArticleId IdType="pubmed">36186125</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y, Zhang Q, Cheng L, Ge J, Wang R, Fang M, et al. . Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against sars-Cov-2. Front Immunol (2022) 13:980435. doi:&#xa0;10.3389/fimmu.2022.980435</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.980435</ArticleId><ArticleId IdType="pmc">PMC9518701</ArticleId><ArticleId IdType="pubmed">36189212</ArticleId></ArticleIdList></Reference><Reference><Citation>Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, et al. . Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (Sars-Cov-2). Pharmacol Res (2020) 156:104761. doi:&#xa0;10.1016/j.phrs.2020.104761</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104761</ArticleId><ArticleId IdType="pmc">PMC7102548</ArticleId><ArticleId IdType="pubmed">32205232</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Liu H, Fan Y, Ji B. Traditional Chinese medicine is effective for covid-19: A systematic review and meta-analysis. Med Nov Technol Devices (2022) 16:100139. doi:&#xa0;10.1016/j.medntd.2022.100139</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medntd.2022.100139</ArticleId><ArticleId IdType="pmc">PMC9066964</ArticleId><ArticleId IdType="pubmed">35527852</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J, Wang YL, Sheng XD, Zhang L, Lv X. Shufeng jiedu capsule inhibits inflammation and apoptosis by activating A2aar and inhibiting nf-Kb to alleviate lps-induced Ali. J Ethnopharmacol (2022) 298:115661. doi:&#xa0;10.1016/j.jep.2022.115661</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2022.115661</ArticleId><ArticleId IdType="pmc">PMC9392900</ArticleId><ArticleId IdType="pubmed">36002086</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei J, Zhou Y, Yang X, Zhang F, Liu X, Yu B. Active components in ephedra sinica stapf disrupt the interaction between Ace2 and sars-Cov-2 rbd: Potent covid-19 therapeutic agents. J Ethnopharmacol (2021) 278:114303. doi:&#xa0;10.1016/j.jep.2021.114303</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2021.114303</ArticleId><ArticleId IdType="pmc">PMC8178536</ArticleId><ArticleId IdType="pubmed">34102269</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Ye F, Sun Q, Liang H, Li C, Li S, et al. . Scutellaria baicalensis extract and baicalein inhibit replication of sars-Cov-2 and its 3c-like protease in vitro. J Enzyme Inhib Med Chem (2021) 36(1):497&#x2013;503. doi:&#xa0;10.1080/14756366.2021.1873977</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14756366.2021.1873977</ArticleId><ArticleId IdType="pmc">PMC7850424</ArticleId><ArticleId IdType="pubmed">33491508</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien LH, Deng JS, Jiang WP, Chen CC, Chou YN, Lin JG, et al. . Study on the potential of sanghuangporus sanghuang and its components as covid-19 spike protein receptor binding domain inhibitors. BioMed Pharmacother (2022) 153:113434. doi:&#xa0;10.1016/j.biopha.2022.113434</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113434</ArticleId><ArticleId IdType="pmc">PMC9288968</ArticleId><ArticleId IdType="pubmed">36076488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wang N, Yang L, Song XQ. Bioactive natural products in covid-19 therapy. Front Pharmacol (2022) 13:926507. doi:&#xa0;10.3389/fphar.2022.926507</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.926507</ArticleId><ArticleId IdType="pmc">PMC9438897</ArticleId><ArticleId IdType="pubmed">36059994</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. . Mrna-lipid nanoparticle covid-19 vaccines: Structure and stability. Int J Pharm (2021) 601:120586. doi:&#xa0;10.1016/j.ijpharm.2021.120586</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120586</ArticleId><ArticleId IdType="pmc">PMC8032477</ArticleId><ArticleId IdType="pubmed">33839230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah A, Qazi J, Rahman L, Kanaras AG, Khan WS, Hussain I, et al. . Nanoparticles-assisted delivery of antiviral-sirna as inhalable treatment for human respiratory viruses: A candidate approach against sars-Cov-2. Nano Sel (2020) 1(6):612&#x2013;21. doi:&#xa0;10.1002/nano.202000125</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nano.202000125</ArticleId><ArticleId IdType="pmc">PMC7675679</ArticleId><ArticleId IdType="pubmed">34485978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zachar O. Nanomedicine formulations for respiratory infections by inhalation delivery: Covid-19 and beyond. Med Hypotheses (2022) 159:110753. doi:&#xa0;10.1016/j.mehy.2021.110753</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2021.110753</ArticleId><ArticleId IdType="pmc">PMC8721932</ArticleId><ArticleId IdType="pubmed">35002023</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunathilake T, Ching YC, Uyama H, Hai ND, Chuah CH. Enhanced curcumin loaded nanocellulose: A possible inhalable nanotherapeutic to treat covid-19. Cellulose (Lond) (2022) 29(3):1821&#x2013;40. doi:&#xa0;10.1007/s10570-021-04391-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10570-021-04391-8</ArticleId><ArticleId IdType="pmc">PMC8725427</ArticleId><ArticleId IdType="pubmed">35002106</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulbah AS, Lee WH. Physicochemical characteristics and in vitro Toxicity/Anti-Sars-Cov-2 activity of favipiravir solid lipid nanoparticles (Slns). Pharm (Basel) (2021) 14(10):1059. doi:&#xa0;10.3390/ph14101059</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14101059</ArticleId><ArticleId IdType="pmc">PMC8540419</ArticleId><ArticleId IdType="pubmed">34681283</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H, Zhao Z, Lan Q, Zhou H, Mai Z, Wang Y, et al. . Nasal delivery of Hesperidin/Chitosan nanoparticles suppresses cytokine storm syndrome in a mouse model of acute lung injury. Front Pharmacol (2020) 11:592238. doi:&#xa0;10.3389/fphar.2020.592238</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.592238</ArticleId><ArticleId IdType="pmc">PMC7873598</ArticleId><ArticleId IdType="pubmed">33584267</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabiei M, Kashanian S, Samavati SS, Derakhshankhah H, Jamasb S, McInnes SJP. Characteristics of sars-Cov2 that may be useful for nanoparticle pulmonary drug delivery. J Drug Target (2022) 30(3):233&#x2013;43. doi:&#xa0;10.1080/1061186x.2021.1971236</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1061186x.2021.1971236</ArticleId><ArticleId IdType="pubmed">34415800</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed Y, El-Maradny YA, Saleh AK, Nayl AA, El-Gendi H, El-Fakharany EM. A comprehensive insight into current control of covid-19: Immunogenicity, vaccination, and treatment. BioMed Pharmacother (2022) 153:113499. doi:&#xa0;10.1016/j.biopha.2022.113499</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113499</ArticleId><ArticleId IdType="pmc">PMC9343749</ArticleId><ArticleId IdType="pubmed">36076589</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary OP, Priyanka, Ahmed JQ, Mohammed TA, Singh I, Rodriguez-Morales AJ. Heterologous prime-boost vaccination against covid-19: Is it safe and reliable? Hum Vaccin Immunother (2021) 17(12):5135&#x2013;8. doi:&#xa0;10.1080/21645515.2021.2007015</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.2007015</ArticleId><ArticleId IdType="pmc">PMC8726007</ArticleId><ArticleId IdType="pubmed">34898381</ArticleId></ArticleIdList></Reference><Reference><Citation>Labouta HI, Langer R, Cullis PR, Merkel OM, Prausnitz MR, Gomaa Y, et al. . Role of drug delivery technologies in the success of covid-19 vaccines: A perspective. Drug Delivery Transl Res (2022) 12(11):2581&#x2013;8. doi:&#xa0;10.1007/s13346-022-01146-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-022-01146-1</ArticleId><ArticleId IdType="pmc">PMC8923087</ArticleId><ArticleId IdType="pubmed">35290656</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Meng Y, Wang K, Zhang X, Chen W, Sheng J, et al. . Inflammation and antiviral immune response associated with severe progression of covid-19. Front Immunol (2021) 12:631226. doi:&#xa0;10.3389/fimmu.2021.631226</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.631226</ArticleId><ArticleId IdType="pmc">PMC7930228</ArticleId><ArticleId IdType="pubmed">33679778</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahmasebi S, Saeed BQ, Temirgalieva E, Yumashev AV, El-Esawi MA, Navashenaq JG, et al. . Nanocurcumin improves treg cell responses in patients with mild and severe sars-Cov2. Life Sci (2021) 276:119437. doi:&#xa0;10.1016/j.lfs.2021.119437</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.119437</ArticleId><ArticleId IdType="pmc">PMC8005319</ArticleId><ArticleId IdType="pubmed">33789145</ArticleId></ArticleIdList></Reference><Reference><Citation>Rarani FZ, Rashidi B, Jafari Najaf Abadi MH, Hamblin MR, Reza Hashemian SM, Mirzaei H. Cytokines and micrornas in sars-Cov-2: What do we know? Mol Ther Nucleic Acids (2022) 29:219&#x2013;42. doi:&#xa0;10.1016/j.omtn.2022.06.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2022.06.017</ArticleId><ArticleId IdType="pmc">PMC9233348</ArticleId><ArticleId IdType="pubmed">35782361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>